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Multiple myeloma (MM) belongs to the group of plasma cell 
neoplasms (Table 1).[1] It is characterised by the neoplastic proliferation 
of plasma cells that produce an abnormal immunoglobulin or 
monoclonal (M) protein. MM accounts for 1% of all cancers and 
~10% of haematological malignancies in the USA.[2] There is a slight 
male predominance, with double the number of African Americans 
affected than whites.[3] The median age at diagnosis is 65 years.[4] The 
South African (SA) National Cancer Registry indicated 347 new cases 
of MM for 2014, which accounted for just ˂1% of all cancers and 
~9% of haematological malignancies. The majority of patients were 
diagnosed in their 70s, with ~18% diagnosed when ˂50 years of age.[5]
MM is usually preceded by an asymptomatic premalignant 
condition, i.e. monoclonal gammopathy of undetermined significance 
(MGUS).[1] MGUS is present in 3 - 4% of people >50 years of age and 
5% of people >70 years of age. The risk of progression to MM is 
1% per year.[6,7] Smouldering multiple myeloma (SMM) is a more 
advanced premalignant phase between MGUS and MM. The risk 
of progression from SMM to MM is 10% per year in the first 5 years, 
followed by 3% per year in the next 5 years, and 1.5% per year 
thereafter.[8] This rate of progression is influenced by underlying 
cytogenetic abnormalities.[9]
The spectrum of presentation of MM varies from asymptomatic to 
aggressive disease, with the most aggressive presentation being that 
of a plasma cell leukaemia (PCL).[1]
Clinical presentation
The symptoms of MM are primarily related to bone infiltration by 
plasma cells or renal tubular damage by excess light chains.[10]
The clinical presentation of MM may be nonspecific. The most 
common presenting symptoms are fatigue, bone pain and anaemia.[4] 
Renal failure may be a presenting feature, and about half of newly 
diagnosed MM patients have a raised creatinine level.[4] Renal 
insufficiency can be due to hypercalcaemia or a myeloma cast 
nephropathy caused by increased serum free light chains. Other 
causes of renal failure include the use of nephrotoxic agents, such 
as non-steroidal anti-inflammatory drugs (NSAIDs) and secondary 
light-chain amyloidosis. 
Hypercalcaemia may be found in approximately one-third of 
patients at diagnosis, and may require urgent therapy. While bone 
pain is present in up to 60% of patients when diagnosed with MM, a 
third of patients may also present with pathological fractures, usually 
of the axial skeleton, but also involving the long bones.[4,11] 
Occasionally, MM may present as a medical emergency owing to 
spinal cord compression by an extradural plasmacytoma or vertebral 
fracture. Furthermore, patients with MM are at increased risk of 
infections due to impaired cell-mediated and humoral immunity. 
Infections due to pneumococcal organisms are most common, but 
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Table 1. Spectrum of plasma cell dyscrasias
MGUS
Plasma cell myeloma, including the following variants
Smouldering multiple myeloma
Non-secretory myeloma
Plasma cell leukaemia
Plasmacytoma
Solitary plasmacytoma of bone
Extramedullary plasmacytoma
Monoclonal immunoglobulin deposition disease
Primary amyloidosis
Systemic light- and heavy-chain deposition diseases
Plasma cell neoplasms associated with paraneoplastic syndromes
POEMS syndrome
TEMPI syndrome (provisional entity)
MGUS = monoclonal gammopathy of undetermined significance;  
POEMS = Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, 
Skin changes; TEMPI = Telangiectasias, Elevated erythropoietin and erythro cytosis, 
Monoclonal gammopathy, Perinephric fluid collection, Intrapulmonary shunting.
Adapted from McKenna et al.[1]
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those due to Haemophilus, Gram-negative organisms and viruses are 
also increased.[10,11]
Approximately 7% of patients with MM may present with extra-
medullary disease only, which is associated with poorer survival.[12] 
Less common clinical presentations include bleeding from platelet 
dysfunction or coagulation abnormalities, and hyperviscosity 
symptoms due to a very high M-protein level. Hepatosplenomegaly 
is unusual, except in cases of amyloid deposition or POEMS 
(Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal 
protein, Skin changes) syndrome. Some patients with MM may be 
diagnosed after an incidental finding of a raised globulin fraction on 
liver function tests performed for other reasons.
Diagnostic approach
Due to the often nonspecific nature of the presenting symptoms 
of MM, one needs to have a high index of suspicion to make the 
diagnosis. MM must be considered in the older patient who presents 
with bone pain, unexplained anaemia, hypercalcaemia or renal 
failure, for which there is no clear cause.
Clinical evaluation
If a diagnosis of MM is suspected, history taking should pay 
particular attention to bone pain, constitutional symptoms, infections 
and neurological complaints. A clinical examination should include 
assessment for pallor, bone tenderness, spinal deformities and 
infections. A neurological examination is mandatory, especially with 
regard to signs of neuropathy and spinal cord compression.[10] 
Investigations
Investigations used in the diagnostic evaluation of MM are aimed 
at demonstrating the M-protein and clonal plasma cells in the bone 
marrow, and evaluating for end-organ damage. Table 2 summarises 
some of these investigations.
Blood investigations
Baseline investigations for MM entail a full blood count (FBC) with a 
differential count and a smear, erythrocyte sedimentation rate (ESR), 
C-reactive protein (CRP) and biochemical tests, including calcium, 
urea and electrolytes (U&E), uric acid and liver function tests  In 
our local setting, hepatitis B and C and HIV testing is usually 
performed.
Common findings on the FBC include a normochromic, 
normocytic anaemia in up to 73% of patients at diagnosis.[4] More 
than 50% of patients demonstrate rouleaux formation on the 
peripheral smear due to high protein levels.[4] Circulating plasma 
cells in the peripheral blood is an uncommon finding, but if present, 
may be indicative of a PCL. MM patients who secrete a heavy-chain 
immunoglobulin have a raised globulin fraction (a high protein with 
normal-low albumin), while the globulin fraction is usually normal 
in patients with only light-chain secretion. The majority of patients 
with MM have decreased levels of uninvolved immunoglobulins 
(immune paresis), which predispose them to infection.
Screening tests to demonstrate the M-protein include a serum 
protein electrophoresis (SPEP) with immunofixation, and a serum 
free light-chain assay or urine protein electrophoresis (UPEP) with 
immunofixation.[13] More than half of patients with MM produce IgG 
heavy-chain M-protein, while 20% produce IgA and a similar number 
secrete only monoclonal light chains (light-chain myeloma).[10] IgD and 
IgM monoclonal proteins are rare, and the differential diagnosis of a 
lymphoplasmacytic lymphoma (Waldenström macroglobulinaemia) 
must be considered in a patient with an IgM paraprotein. Patients 
with light-chain myeloma have a normal SPEP, with light chains 
detected on the serum free light-chain assay and UPEP. About 
2 - 3% of patients have true non-secretory MM with no detectable 
M-protein in the serum or urine; these patients require imaging and 
bone marrow biopsy for diagnosis and monitoring.[4,10] 
Bone marrow examination
In 2014, the International Myeloma Working Group (IMWG) revised 
the criteria for the diagnosis of MM and related disorders. Table 3 lists 
the diagnostic criteria for MM and related plasma cell disorders.[2]
This major revision was to include a subset of patients with 
previous SMM, who displayed 1 of 3 specific biomarkers in the 
category of MM.[2] Each biomarker is associated with an 80% 
Table 2. Relevant investigations in multiple myeloma
Baseline blood tests
Full blood count with differential count and smear
Urea and electrolytes
Total protein and albumin
Calcium
Uric acid
Erythrocyte sedimentation rate
C-reactive protein
Viral screen (HIV, hepatitis B and C)
Screening tests
Serum protein electrophoresis
Serum free light chains or 24-hour urine protein electrophoresis
Confirmatory tests
Bone marrow aspirate and trephine, immunohistochemistry and/or flow cytometry
Imaging
PET/CT, whole-body low-dose CT, MRI or skeletal survey
Tests for risk stratification
Lactate dehydrogenase
Beta-2 microglobulin
FISH/cytogenetics
PET/CT = positron emission tomography/computed tomography; MRI = magnetic resonance imaging; FISH = fluorescent in situ hybridisation.
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2-year risk of progression to end-organ damage. These biomarkers, 
together with the CRAB (hyperCalcaemia, Renal failure, Anaemia, 
Bone lesions) criteria, are known as myeloma-defining events. This 
revision of the criteria for MM has resulted in a paradigm shift, 
as a subset of patients with SMM are now treated earlier, prior to 
developing end-organ damage.
A bone marrow aspirate and trephine biopsy is key to the definitive 
diagnosis of MM. 
Plasma cell clonality is demonstrated on flow cytometry or 
immunohistochemistry. Fluorescent in situ hybridisation (FISH) 
studies aid with molecular characterisation of MM, which is 
important for therapeutic decisions and prognostication (see Risk 
stratification below).[14] 
Imaging 
Advanced imaging modalities are more sensitive for the diagnosis of 
MM and have largely replaced the skeletal survey in the developed 
world. Imaging techniques include whole-body, low-dose computed 
tomography (CT) scanning, fluorodeoxyglucose F18 (18F-FDG) positron 
emission tomography/CT (PET/CT) and magnetic resonance imaging 
(MRI). PET/CT is more sensitive for soft-tissue lesions, while MRI has 
superior sensitivity for focal bone marrow involvement.[15] MRI is also 
useful in cases of suspected spinal cord compression.
A skeletal survey examination (skull, ribs, spine, pelvis, humerus 
and femur radiographs) is useful in a setting where more specialised 
imaging is not available. Abnormalities on skeletal survey include 
punched-out lytic bone lesions, generalised osteopenia and vertebral 
compression fractures.
Risk stratification
MM is a heterogeneous disease, with the clinical presentation 
being quite aggressive in some patients, while patients with SMM 
do not require treatment. The median overall survival of patients 
with MM is ~6 years. Patient- and disease-related factors affect 
treatment response and overall survival.[16] Important patient factors 
include age, performance status and presence of comorbidities, all of 
which influence the type of induction chemotherapy and transplant 
eligibility. Disease-related factors include tumour burden and 
cytogenetics. Staging of MM was previously done according to the 
Salmon-Durie classification, which involved assessment of tumour 
burden by degree of anaemia, hypercalcaemia, creatinine, extent of 
lytic bone disease and immunoglobulin levels.[17] This classification 
has largely been replaced by the Revised International Staging System 
(R-ISS) for MM, which incorporates markers of tumour burden, such 
as albumin and beta-2 microglobulin, as well as indicators of tumour 
biology, such as lactate dehydrogenase and cytogenetics (Table 4).[18] 
Table 3. Diagnostic criteria for monoclonal gammopathy of undetermined significance, smouldering multiple myeloma and 
multiple myeloma
MGUS 
M-protein <30 g/L in the serum
<10% clonal plasma cells in the bone marrow
Absence of myeloma-defining events or amyloid  
SMM
Both criteria must be met
Serum M-protein ≥30 g/L, and/or urine M-protein ≥500 mg/24 h, and/or bone marrow clonal plasmacytosis 10 - 60%
Absence of myeloma-defining events or amyloid
MM
 Clonal bone marrow plasmacytosis ≥10% or biopsy-proven plasmacytoma, PLUS any one of the following myeloma-defining events or 
biomarkers of malignancy
HyperCalcaemia: serum calcium >2.75 mmol/L or >0.25 mmol/L higher than the upper limit of normal 
Renal insufficiency: creatinine clearance <40 mL/min or serum creatinine >177 µmol/L
Anaemia: Hb <10 g/dL or >2 g/dL below the lower limit of normal
Bone lesions: ≥1 osteolytic lesion(s) on skeletal survey, CT or PET/CT
Clonal bone marrow plasmacytosis ≥60%
Involved-to-uninvolved serum free light ratio ≥100
>1 focal lesion on MRI
MGUS = monoclonal gammopathy of undetermined significance; M-protein = monoclonal protein; SMM = smouldering multiple myeloma; MM = multiple myeloma;  
CT = computed tomography; PET/CT = positron emission tomography/computed tomography; MRI = magnetic resonance imaging.
Adapted from McKenna et al.[1]
Table 4. The Revised International Staging System for multiple myeloma
Stage Patients, % 5-year survival, %
Stage l
Albumin >35 g/L and beta-2 microglobulin <3.5 mg/L
Normal LDH
No high-risk cytogenetics
28 82
Stage ll 
Not fulfilling criteria for stage l or lll
62 62
Stage lll
Beta-2 microglobulin >5.5 mg/L
Raised LDH or high-risk cytogenetics (t(4;14), t(14;16) or deletion(17p))
10 40
LDH = lactate dehydrogenase.
Adapted from Palumbo et al.[18}
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The R-ISS is easy to use and more objective than the Salmon-Durie 
classification.[10] 
Management 
The standard of care for patients with MGUS and SMM is observation. 
Treatment is indicated in all patients who fulfil the IMWG criteria 
for the diagnosis of MM. Without treatment, the median survival 
is 6 months.[19] The management of MM consists of supportive and 
specific measures.
Supportive management and adjunctive therapies
The supportive aspect of management is crucial in MM. This is borne 
out by the observation of newly diagnosed patients entered into the 
UK’s Medical Research Council (MRC) trials, where there was a 10% 
rate of early death of patients with MM (within 60 days), mainly due 
to infection, followed by renal failure.[20]
Patients presenting as medical emergency cases require prompt 
intervention. Urgent radiotherapy is indicated in acute spinal 
cord compression. Severe hypercalcaemia of rapid onset requires 
urgent isotonic hydration, steroids and intravenous bisphospho-
nate therapy (pamidronate or zoledronic acid).[10] Patients with 
uncommon presentations of hyperviscosity syndrome need prompt 
plasmapheresis.
Care should be taken to avoid exacerbation of pre-existing renal 
impairment. Nephrotoxic drugs such as aminoglycosides and 
NSAIDs must be avoided, and patients should maintain adequate 
hydration. Infections must be managed promptly, and patients 
must receive pneumococcal and influenza vaccines.[10] Appropriate 
analgesia is important for management of bone pain. 
Reversible underlying causes of anaemia must be treated. Patients 
with acute, symptomatic anaemia require blood transfusion. 
Erythropoiesis-stimulating agents may be used during the course 
of the disease, albeit with caution, owing to the increased risk of 
thrombosis associated with these agents.[10] 
Bisphosphonate therapy is integral to the management of 
MM patients with symptomatic bone disease and lytic lesions 
or osteopenia on imaging. Apart from treating hypercalcaemia, 
bisphosphonates improve bone pain, decrease skeletal-related events 
and have an anti-tumour effect. There is a role for surgery for fixation 
of pathological or impending fractures of the long bones, as well as 
spinal cord decompression of vertebral fragments. Vertebroplasty 
or kyphoplasty are useful adjuncts to pain control. Radiotherapy is 
also used for intractable bone pain and for the treatment of solitary 
plasmacytomas.
Principles of specific treatment
Treatment is dictated by transplant eligibility, risk stratification 
and available resources. Transplant eligibility is determined by age, 
performance status and comorbidities. In general, fit patients up to 
the age of 65 - 70 years are considered for transplant. Drug availability 
due to high costs of newer agents, as well as access to transplantation, 
is a major challenge in resource-constrained environments.[21]
Transplant-eligible patients
Induction chemotherapy for 3 - 4 cycles followed by high-dose therapy 
and autologous stem cell transplantation (ASCT) is the standard of 
care for MM patients who are eligible for transplant. ASCT is not 
curative, but improves event-free and overall survival compared with 
chemotherapy alone.[10] Several triplet regimens are recommended, 
most of which include a proteasome inhibitor, immunomodulatory 
agent and dexamethasone. Table 5 alludes to the different classes 
of agents available. Choice of regimen is guided by disease biology, 
patient characteristics, drug availability and regional guidelines. 
Some common regimens include bortezomib, lenalidomide and 
dexamethasone; bortezomib, cyclophosphamide and dexamethasone; 
and bortezomib, thalidomide and dexamethasone.[8] The pros and 
cons of the various regimens are beyond the scope of this review. 
Trials of maintenance therapy after ASCT (bortezomib-based or 
lenalidomide) have shown improved progression-free and overall 
survival.[22-24) 
Transplant-ineligible patients
Patients who are transplant ineligible may be treated with the same 
regimens as transplant-eligible patients if they can tolerate these 
regimens (for 8 - 12 months), but such patients can also receive dual-
therapy regimens and melphalan-containing regimens (for up to 18 
months). 
The role of maintenance in this group of patients is less clear.[8]
Treatment monitoring and relapse
The IMWG uniform response criteria is used to monitor treatment 
response and relapse of MM.[25] Patients are monitored at clinic visits 
by SPEP and serum FLC levels or 24-h UPEP. Almost all patients with 
MM relapse. Management of relapsed/refractory MM is beyond the 
scope of this article, but there is a clear role for novel agents such as 
monoclonal antibodies in this setting.
Summary 
• MM belongs to the group of plasma cell neoplasms and is 
characterised by the production of a monoclonal protein 
(M-protein).
• The most common presenting symptoms of MM are fatigue, 
anaemia and bone pain.
• One must have a high index of suspicion to diagnose MM in the 
older patient who presents with nonspecific symptoms.
• Renal impairment is common in MM, and nephrotoxic agents 
must be avoided in these patients.
• Spinal cord compression, hypercalcaemia and hyperviscosity 
syndrome are medical emergencies, and should be managed as 
such.
• A bone marrow aspirate and trephine biopsy are mandatory for the 
definitive diagnosis of MM.
• The skeletal survey, although largely replaced by modern imaging, 
still has a useful place in the local setting.
Table 5. Drugs to treat multiple myeloma
Class of drug Examples
Proteasome inhibitors Bortezomib
Carfilzomib
Ixazomib
Immunomodulatory agents Thalidomide
Lenalidomide
Pomalidomide
Monoclonal antibodies Daratumumab
Elotuzumab
Histone deacetylase inhibitors Panobinostat
Alkylating agents Melphalan
Cyclophosphamide
Bendamustine
Antitumour antibiotics Doxorubicin
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• The supportive management of patients with MM is crucial, 
and includes maintaining adequate hydration, administering 
appropriate analgesia and managing concurrent infections.
• Treatment is dictated by transplant eligibility, with ASCT currently 
being the standard of care in younger, fit patients.
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